Aaron Gardner advises life sciences companies on a broad spectrum of complex transactions.
Mr. Gardner draws on extensive experience structuring and negotiating high-stakes deals in the pharmaceutical, biotechnology, medical, and consumer nutrition sectors, including:
- Mergers, acquisitions, and divestitures
- Licensing and collaborations, including agreements for research and development, co-commercialization and co-promotion, platform technology, co-commercialization and co-promotion, companion diagnostic development, and manufacturing and supply
- Private equity transactions
He helps clients navigate transactions spanning the entire product life cycle and across therapeutic areas and modalities, frequently involving the cutting-edge technologies that rapidly change the face of medicine.
Before joining Latham, Mr. Gardner was a partner at another global law firm. He previously served as senior M&A counsel for a global biopharmaceutical company, which provided him with a real-world understanding of the in-house corporate legal function and substantial experience counseling corporate executives on a wide range of legal and commercial issues.